38. Cost effectiveness of Lenvatinib as treatment for hepatocellular carcinoma (hcc): A literature review
Main Article Content
Abstract
Hepatocellular carcinoma is a growing economic and disease burden, especially for patients who have advanced or unresectable hepatocellular carcinoma. Lenvatinib treatment improves overall survival and slows disease progression compared to Sorafenib, but its high cost poses challenges for patients. A literature review was conducted to evaluate the cost-effectiveness on Lenvatinib compared to other treatment options for HCC based on PubMed, Cochrane, Web of Science, Hinari databases published within the last 10 years. 7 out of 9 studies showed Lenvatinib to be cost-effective in many countries, but 2 studies in China showed other options to be more favorable due to the high cost of Lenvatinib. Therefore, reducing the price of these systemic drugs below the payment threshold of each country is a favorable factor for patients with unresectable hepatocellular carcinoma for easier access and maximize cost effectiveness. On this basis, we suggest to add Lenvatinib to the Vietnam Health Insurance Drug List.
Article Details
Keywords
Hepatocellular carcinoma, cost-effectiveness, lenvatinib, literature review
References
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249. doi:10.3322/caac.21660.
2. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2): 223-238. doi:10.1016/j.cld.2015.01.001.
3. Lang L. FDA Approves Sorafenib for Patients With Inoperable Liver Cancer. Gastroenterology. 2008; 134(2): 379. doi:10.1053/j.gastro.2007.12.037.
4. EMA. Lenvima. European Medicines Agency. Published September 17, 2018. Accessed April 15, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima.
5. Research C for DE and. FDA approves lenvatinib for unresectable hepatocellular carcinoma. FDA. Published online March 11, 2018. Accessed April 15, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-unresectable-hepatocellular-carcinoma.
6. Cục Quản lý Dược - Bộ Y tế. Tổng hợp báo cáo KQTT của các đơn vị báo cáo, cập nhật đến ngày 06/02/2023. Published February 13, 2023. Accessed May 11, 2023. https://dav.gov.vn/tong-hop-bao-cao-kqtt-cua-cac-don-vi-bao-cao-cap-nhat-den-ngay-06022023-n3835.html.
7. Riva JJ, Malik KMP, Burnie SJ, Endicott AR, Busse JW. What is your research question? An introduction to the PICOT format for clinicians. J Can Chiropr Assoc. 2012; 56(3): 167-171. Accessed May 12, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430448/.
8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. doi:10.1136/bmj.n71.
9. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013; 346: f1049. doi:10.1136/bmj.f1049.
10. Kobayashi M, Kudo M, Izumi N, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019; 54(6): 558-570. doi:10.1007/s00535-019-01554-0.
11. Cai H, Zhang L, Li N, Zheng B, Liu M. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. J Comp Eff Res. 2020; 9(8): 553-562. doi:10.2217/cer-2020-0041.
12. Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. Clin Drug Investig. 2020; 40(12): 1167-1176. doi:10.1007/s40261-020-00983-7.
13. Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2020; 25(3): e512-e519. doi:10.1634/theoncologist.2019-0501.
14. Meyers BM, Vogel A, Marotta P, et al. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. Canadian Journal of Gastroenterology and Hepatology. 2021; 2021: e8811018. doi:10.1155/2021/8811018.
15. Ikeda S, Kudo M, Izumi N, et al. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. Value Health Reg Issues. 2021; 24: 82-89. doi:10.1016/j.vhri.2020.05.009.
16. Sun KX, Cao SS, Shi FH, et al. First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therap Adv Gastroenterol. 2022; 15: 17562848221140662. doi:10.1177/17562848221140662.
17. Zhao M, Pan X, Yin Y, et al. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. Front Public Health. 2022; 10: 869960. doi:10.3389/fpubh.2022.869960.
18. Zhou T, Wang X, Cao Y, et al. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res. 2022; 22(1): 1367. doi:10.1186/s12913-022-08661-4.
19. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126): 1163-1173. doi:10.1016/S0140-6736(18)30207-1.
20. Cục Quản lý Dược - Bộ Y tế. Thông tư 30/2018/TT-BYT thanh toán thuốc hóa dược sinh phẩm của người tham gia bảo hiểm y tế. Published March 1, 2023. Accessed April 15, 2023. https://thuvienphapluat.vn/van-ban/Bao-hiem/Thong-tu-30-2018-TT-BYT-thanh-toan-thuoc-hoa-duoc-sinh-pham-cua-nguoi-tham-gia-bao-hiem-y-te-400326.aspx.
2. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2): 223-238. doi:10.1016/j.cld.2015.01.001.
3. Lang L. FDA Approves Sorafenib for Patients With Inoperable Liver Cancer. Gastroenterology. 2008; 134(2): 379. doi:10.1053/j.gastro.2007.12.037.
4. EMA. Lenvima. European Medicines Agency. Published September 17, 2018. Accessed April 15, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima.
5. Research C for DE and. FDA approves lenvatinib for unresectable hepatocellular carcinoma. FDA. Published online March 11, 2018. Accessed April 15, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-unresectable-hepatocellular-carcinoma.
6. Cục Quản lý Dược - Bộ Y tế. Tổng hợp báo cáo KQTT của các đơn vị báo cáo, cập nhật đến ngày 06/02/2023. Published February 13, 2023. Accessed May 11, 2023. https://dav.gov.vn/tong-hop-bao-cao-kqtt-cua-cac-don-vi-bao-cao-cap-nhat-den-ngay-06022023-n3835.html.
7. Riva JJ, Malik KMP, Burnie SJ, Endicott AR, Busse JW. What is your research question? An introduction to the PICOT format for clinicians. J Can Chiropr Assoc. 2012; 56(3): 167-171. Accessed May 12, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430448/.
8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. doi:10.1136/bmj.n71.
9. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013; 346: f1049. doi:10.1136/bmj.f1049.
10. Kobayashi M, Kudo M, Izumi N, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019; 54(6): 558-570. doi:10.1007/s00535-019-01554-0.
11. Cai H, Zhang L, Li N, Zheng B, Liu M. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. J Comp Eff Res. 2020; 9(8): 553-562. doi:10.2217/cer-2020-0041.
12. Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. Clin Drug Investig. 2020; 40(12): 1167-1176. doi:10.1007/s40261-020-00983-7.
13. Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2020; 25(3): e512-e519. doi:10.1634/theoncologist.2019-0501.
14. Meyers BM, Vogel A, Marotta P, et al. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. Canadian Journal of Gastroenterology and Hepatology. 2021; 2021: e8811018. doi:10.1155/2021/8811018.
15. Ikeda S, Kudo M, Izumi N, et al. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. Value Health Reg Issues. 2021; 24: 82-89. doi:10.1016/j.vhri.2020.05.009.
16. Sun KX, Cao SS, Shi FH, et al. First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therap Adv Gastroenterol. 2022; 15: 17562848221140662. doi:10.1177/17562848221140662.
17. Zhao M, Pan X, Yin Y, et al. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. Front Public Health. 2022; 10: 869960. doi:10.3389/fpubh.2022.869960.
18. Zhou T, Wang X, Cao Y, et al. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res. 2022; 22(1): 1367. doi:10.1186/s12913-022-08661-4.
19. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126): 1163-1173. doi:10.1016/S0140-6736(18)30207-1.
20. Cục Quản lý Dược - Bộ Y tế. Thông tư 30/2018/TT-BYT thanh toán thuốc hóa dược sinh phẩm của người tham gia bảo hiểm y tế. Published March 1, 2023. Accessed April 15, 2023. https://thuvienphapluat.vn/van-ban/Bao-hiem/Thong-tu-30-2018-TT-BYT-thanh-toan-thuoc-hoa-duoc-sinh-pham-cua-nguoi-tham-gia-bao-hiem-y-te-400326.aspx.